Engineered immune cells take on tough T-Cell cancers
NCT ID NCT07300683
First seen Dec 29, 2025 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This early-phase trial is testing a new type of immunotherapy called CAR T cells, made from a patient's own blood cells, to treat T-cell acute lymphoblastic leukemia and lymphoma that has relapsed or not responded to standard treatments. The CAR T cells are designed to target a protein called CCR9 found on the cancer cells. The main goals are to see if the treatment can be made safely and to find the right dose, with 24 children and adults participating.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University College London Hospitals
RECRUITINGLondon, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-CCR9 CAR T cells (made from the patient's own blood cells)
What this could lead to
If it works, this could lead to a new treatment option for people with T-cell leukemia or lymphoma that has come back or not responded to standard therapy.
What could go wrong
This is a very early Phase 1 trial with only 24 people, so it is primarily testing safety and dosing. The treatment may not work, and there are risks of serious side effects from the chemotherapy and the CAR T cells themselves.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.